RxDoctor Payments Data

Daniel Elgut, DPM

Foot & Ankle Surgery · Royal Palm Beach, FLNPI 1215354352

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $53,740 of the $72,571 with a category attached, or 74.1%. 38 manufacturers reported payments, led by Flower Orthopedics Coporation at 59.6% of the total. Reporting peaked in 2020 at $32,114 and has fallen 96.1% since, to $1,249 in 2025. Among foot & ankle surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,571in general payments, 2019–2025

Across 280 payments — averaging $259.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Flower Orthopedics Coporation$43K
  • Avitus Orthopaedics, Inc.$7K
  • In2bones USA, LLC$7K
  • Bone Support Inc.$4K
  • Stryker$4K
  • Linvatec Corporation$2K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$53,74074%
  • Speaking & faculty fees$1,5002%
  • Travel & lodging$3,2705%
  • Food & beverage$14,06119%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,571 in reported general payments places this provider in the 95th percentile of 850 foot & ankle surgery providers in Florida.

See all foot & ankle surgery providers in Florida

Medicare billing

Part B allowed, 2024
$552,323
Medicare patients
704
Services billed
3,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$3,699
Cephalexin49$519
Gabapentin92$355
Methylprednisolone47$265
Ciclopirox14$258
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$252
Celecoxib16$246
Mupirocin23$198
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$146
Doxycycline Hyclate26$137
Ciprofloxacin Hcl14$52
Ondansetron Hcl12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$83$3,69911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 850 foot & ankle surgery providers in Florida.

Other foot & ankle surgery in Royal Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →